Neurogene Inc. (NGNE)
NASDAQ: NGNE · Real-Time Price · USD
20.28
-0.88 (-4.16%)
At close: Dec 5, 2025, 4:00 PM EST
20.26
-0.02 (-0.10%)
After-hours: Dec 5, 2025, 5:01 PM EST
Neurogene Revenue
In the year 2024, Neurogene had annual revenue of $925.00K.
Revenue (ttm)
$925.00K
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
107
Market Cap
314.13M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 925.00K | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionNGNE News
- 1 day ago - Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 12 days ago - Neurogene: From Speculation To Execution With NGN-401 - Seeking Alpha
- 22 days ago - Neurogene Reports Third Quarter 2025 Financial Results and Highlights Recent Updates - Business Wire
- 23 days ago - Neurogene Inc. (NGNE) Presents at Stifel 2025 Healthcare Conference Transcript - Seeking Alpha
- 23 days ago - Neurogene Reports Positive Interim Data in Pediatric Cohort from NGN-401 Gene Therapy Trial for Rett Syndrome - Business Wire
- 4 weeks ago - Neurogene Announces First Participant Dosed in Embolden™ Registrational Trial of NGN-401 Gene Therapy for Rett Syndrome - Business Wire
- 4 weeks ago - Neurogene Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 2 months ago - Neurogene Announces Positive Regulatory Update for NGN-401 Gene Therapy in Rett Syndrome with Plans to Initiate Dosing in Embolden™ Registrational Trial in Q4 2025 - Business Wire